Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:CNTB NASDAQ:FULC NASDAQ:PRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.31-0.6%$3.09$1.05▼$3.97$374.62M2628,960 shs310,947 shsCNTBConnect Biopharma$1.56-4.3%$1.86$0.51▼$2.86$90.83M-0.09149,569 shs177,038 shsFULCFulcrum Therapeutics$7.00+0.1%$7.08$2.32▼$8.50$378.10M2.82390,128 shs353,055 shsPRTCPureTech Health$15.80-3.1%$17.97$13.30▼$24.99$393.59M1.115,010 shs1,787 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+2.47%-2.41%+13.29%-8.02%+12.90%CNTBConnect Biopharma-7.39%-8.43%-28.19%+71.58%+29.37%FULCFulcrum Therapeutics0.00%+1.60%+6.88%+2.04%-21.02%PRTCPureTech Health+3.49%-1.49%-9.51%-16.83%-18.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.31-0.6%$3.09$1.05▼$3.97$374.62M2628,960 shs310,947 shsCNTBConnect Biopharma$1.56-4.3%$1.86$0.51▼$2.86$90.83M-0.09149,569 shs177,038 shsFULCFulcrum Therapeutics$7.00+0.1%$7.08$2.32▼$8.50$378.10M2.82390,128 shs353,055 shsPRTCPureTech Health$15.80-3.1%$17.97$13.30▼$24.99$393.59M1.115,010 shs1,787 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+2.47%-2.41%+13.29%-8.02%+12.90%CNTBConnect Biopharma-7.39%-8.43%-28.19%+71.58%+29.37%FULCFulcrum Therapeutics0.00%+1.60%+6.88%+2.04%-21.02%PRTCPureTech Health+3.49%-1.49%-9.51%-16.83%-18.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75134.14% UpsideCNTBConnect Biopharma 3.50Strong Buy$7.00348.72% UpsideFULCFulcrum Therapeutics 3.00Buy$9.6037.14% UpsidePRTCPureTech Health 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CNTB, PRTC, ADCT, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/13/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.007/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00 ➝ $10.006/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M5.26N/AN/A($2.10) per share-1.58CNTBConnect Biopharma$26.03M3.34N/AN/A$1.67 per share0.93FULCFulcrum Therapeutics$80M4.73N/AN/A$4.51 per share1.55PRTCPureTech Health$4.83M78.93$2.31 per share6.84$17.04 per share0.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/AN/AFULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/AN/ALatest CNTB, PRTC, ADCT, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ADCTADC Therapeutics-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 million7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.934.66CNTBConnect Biopharma0.017.247.24FULCFulcrum TherapeuticsN/A24.4224.42PRTCPureTech HealthN/A8.499.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%CNTBConnect Biopharma58.72%FULCFulcrum Therapeutics89.83%PRTCPureTech Health0.04%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%CNTBConnect Biopharma22.60%FULCFulcrum Therapeutics7.00%PRTCPureTech Health5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310112.50 million106.42 millionOptionableCNTBConnect Biopharma11055.72 million43.13 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionablePRTCPureTech Health10024.13 million22.85 millionNot OptionableCNTB, PRTC, ADCT, and FULC HeadlinesRecent News About These CompaniesShort Interest in PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Expands By 53.1%September 9 at 2:38 PM | marketbeat.comPureTech Health (NASDAQ:PRTC) Trading 4.7% Higher - What's Next?September 7, 2025 | marketbeat.comPureTech Health plc (NASDAQ:PRTC) Q2 2025 Earnings Call TranscriptAugust 29, 2025 | insidermonkey.comPureTech Health plc (PRTC) Q2 2025 Earnings Conference Call TranscriptAugust 28, 2025 | seekingalpha.comPureTech Health plc – Half-Year ReportAugust 28, 2025 | businesswire.comPureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Down 39.6% in JulyAugust 21, 2025 | marketbeat.comPureTech Health: Notice of Half-Yearly ResultsAugust 18, 2025 | businesswire.comPureTech Health (NASDAQ:PRTC) Trading Up 1.4% - Still a Buy?August 15, 2025 | marketbeat.comPureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary EndpointAugust 13, 2025 | businesswire.comPureTech Health plc: PureTech Announces Board ChangeJuly 31, 2025 | finanznachrichten.dePureTech CEO Bharatt Chowrira steps downJuly 16, 2025 | thepharmaletter.comTPureTech Health CEO Bharatt Chowrira ResignsJuly 16, 2025 | marketwatch.comPureTech Announces Leadership TransitionJuly 16, 2025 | businesswire.comPureTech Health announces board chair Raju Kucherlapati steps downJuly 10, 2025 | investing.comPureTech Health plc (PRTC) Income Statement - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comPureTech Announces Board ChangeJuly 8, 2025 | businesswire.comWhy This Biotech Stock Just Doubled In A Single DayJune 26, 2025 | benzinga.comPureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF TrialMay 22, 2025 | businesswire.comPureTech’s deupirfenidone shows strong and durable efficacyMay 21, 2025 | thepharmaletter.comTPureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)May 9, 2025 | businesswire.comPureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International ConferenceMay 1, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTB, PRTC, ADCT, and FULC Company DescriptionsADC Therapeutics NYSE:ADCT$3.31 -0.02 (-0.60%) Closing price 03:59 PM EasternExtended Trading$3.30 0.00 (-0.15%) As of 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Connect Biopharma NASDAQ:CNTB$1.56 -0.07 (-4.29%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.01 (+0.96%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Fulcrum Therapeutics NASDAQ:FULC$7.00 +0.01 (+0.14%) Closing price 04:00 PM EasternExtended Trading$7.00 0.00 (0.00%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.PureTech Health NASDAQ:PRTC$15.60 -0.71 (-4.35%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
